Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. (IMTX) is a clinical-stage biopharmaceutical leader developing T-cell redirecting immunotherapies for cancer treatment. This news hub provides investors and researchers with timely updates on groundbreaking therapies targeting solid and liquid tumors through proprietary platforms like Xpresient® and TCER® molecules.
Access consolidated coverage of press releases, clinical trial milestones, and strategic partnerships. Track developments in adoptive cell therapies and bispecific TCR molecules designed to enhance precision oncology outcomes. Our repository ensures you never miss critical updates about FDA interactions, collaborative research advancements, or pipeline expansions.
Key content categories include clinical program updates, partnership announcements with major industry players, financial disclosures, and scientific presentations. All materials are vetted for relevance to investment analysis and therapeutic innovation.
Bookmark this page for streamlined access to Immatics' latest achievements in immuno-oncology. Check regularly for authoritative reporting on their mission to redefine cancer treatment through engineered T-cell therapies.
Immatics N.V. (NASDAQ: IMTX) has announced updates on its clinical trial ACTengine® IMA203, which will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The oral presentation on November 13 will cover safety and anti-tumor activity in advanced solid cancers, while a preclinical data update on CD8 TCR-T will be presented as a poster on November 12. These updates reflect Immatics’ commitment to enhancing cancer immunotherapy.
Immatics (NASDAQ: IMTX) reported its financial results for Q2 2021, revealing a net loss of €23.8 million ($28.3 million), up from €21.3 million ($25.3 million) in Q2 2020. The company's cash and cash equivalents stood at €192.8 million ($229.1 million) as of June 30, 2021. Patient recruitment for the ACTengine® programs continues positively, with 27 patients treated by the end of July. Immatics is advancing its TCR Bispecifics pipeline, anticipating the submission of a Clinical Trial Application for IMA401 in Q4 2021. Key upcoming data releases are expected in the second half of 2021.
BioCopy AG has partnered with Immatics N.V. (NASDAQ: IMTX) to enhance T cell receptor (TCR) characterization, crucial in cancer immunotherapy. The collaboration aims to innovate high-throughput screening for TCR-peptide-HLA interactions, supporting the development of TCR-based therapies. BioCopy's patented technology can analyze over 5,000 interactions simultaneously, potentially expediting pre-clinical safety assessments. Rainer Böhm of BioCopy emphasized their unique platform addressing oncology and infectious diseases, while Immatics plans to integrate this into its XCEPTOR® platform for targeted cancer therapies.
Immatics N.V. (NASDAQ: IMTX) announced a leadership change on May 26, 2021, as Christof Hettich steps down from its Board of Directors after 15 years. He will be succeeded by Friedrich von Bohlen und Halbach, a former board member, at the Annual General Meeting scheduled for June 17, 2021. Hettich’s contributions were praised by Peter Chambré, Chairman of the Board. Von Bohlen und Halbach brings extensive experience in biopharmaceuticals, previously holding significant roles in several leading biotech firms.
Immatics reported promising updates on its ACTengine® IMA200 clinical trials, revealing anti-tumor activity in heavily pre-treated patients. The first quarter of 2021 showed a revenue of €7.4 million, a slight increase from €7.0 million in Q1 2020. However, R&D expenses surged to €23.0 million, up from €12.2 million, contributing to a net loss of €21.6 million. As of March 31, 2021, Immatics maintained a solid cash position of €216.7 million, ensuring operational funding into 2023. The next data update for ACTengine® is expected in H2 2021.
Immatics announced positive preclinical results for its second TCR Bispecific program, IMA402, demonstrating tumor cell killing in vitro and complete regression of established tumors in an in vivo model. Targeting the PRAME peptide, IMA402 showed anti-tumor activity against PRAME-positive cancers, indicating a broad potential patient population. The clinical lead candidate has been selected and GMP manufacturing activities initiated, positioning IMA402 for submission towards IND development.
Immatics N.V. (NASDAQ: IMTX) provided a Phase 1a data update on its ACTengine® programs, reporting positive anti-tumor activity in heavily pre-treated solid cancer patients. As of December 31, 2020, the company had cash and equivalents of €232 million ($285 million), ensuring funding into 2023. Revenue for 2020 increased to €31.3 million ($38.4 million), while R&D expenses rose significantly to €67.1 million ($82.3 million). The net loss for 2020 was €229.6 million ($281.7 million), largely due to a non-cash expense tied to the ARYA merger. Additional data updates on trials are expected in H2 2021.
Immatics N.V. (NASDAQ: IMTX) announced promising early results from its ongoing Phase 1 clinical trials for engineered T cell therapies targeting solid tumors. Anti-tumor activity was observed in 9 out of 10 evaluable patients, with tumor shrinkage noted in 8 patients and one confirmed partial response. Adverse events were transient and manageable, with no major safety issues. The trials utilized low initial doses of the ACTengine® product candidates IMA201, IMA202, and IMA203. CEO Harpreet Singh highlighted the unexpected anti-tumor activity given the heavily pre-treated patient population.
Immatics N.V. (NASDAQ: IMTX) reported significant progress in its ACTengine® IMA200 clinical trial series, with seven sites in operation and initial data expected in Q1 2021. The partnership with UTHealth extends cell therapy manufacturing until 2024, enhancing operational capacity. Financially, the company holds €259.3 million ($303.6 million) in cash as of September 30, 2020. Revenue reached €7.8 million ($9.1 million) for Q3 2020, up from €5.1 million ($6.0 million) in 2019. However, a net loss of €177.1 million ($207.3 million) reflects a significant one-time expense related to the ARYA merger.
Immatics N.V. (NASDAQ: IMTX) announced promising Phase I results from its ACTolog® program, demonstrating the feasibility and tolerability of a personalized multi-target T cell therapy for cancer. The study involved 14 patients with relapsed/refractory solid tumors, highlighting a target positivity rate of 90% and significant T cell persistence. Notably, three patients exhibited long-term disease stabilization. The results suggest further evaluation of multi-target adoptive cell therapy using potent T cell receptors, especially targeting COL6A3 exon 6 as a valuable tumor target.
